Clovis Oncology Exploring Ways to Improve Cash Position, Fund Operations Beyond 2023
During a call to discuss Q2 financials, the company reported a 13 percent year-over-year decrease in Rubraca revenues and said it is exploring strategies to raise additional capital.
Source: precisiononcologynews.com